AbbVie Inc. Receivables

Receivables of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Receivables growth rates and interactive chart. Accounts receivable (AR) is the balance of money due to a firm for goods or services delivered or used but not yet paid for by customers. Accounts receivables are listed on the balance sheet as a current asset. AR is any amount of money owed by customers for purchases made on credit. When a company makes a sale, it records revenues and a corresponding balance in accounts receivable. When an invoice is paid, the accounts payable account is reduced and cash is received. Receivables should grow in-line with revenue over time, if they are growing much faster, a company might be booking revenue too aggressively.

Highlights and Quick Summary

  • Receivables for the quarter ending September 29, 2021 was $9.28 Billion (a -6.38% decrease compared to previous quarter)
  • Year-over-year quarterly Receivables increased by 5.2%
  • Annual Receivables for 2020 was $8.82 Billion (a 62.53% increase from previous year)
  • Annual Receivables for 2019 was $5.43 Billion (a 0.82% increase from previous year)
  • Annual Receivables for 2018 was $5.38 Billion (a 5.82% increase from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Receivables of AbbVie Inc.

Most recent Receivablesof ABBV including historical data for past 10 years.

Interactive Chart of Receivables of AbbVie Inc.

AbbVie Inc. Receivables for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 – $9,281.0 $9,914.0 $9,588.0 –
2020 $8,822.0 $8,416.0 $8,354.0 $6,362.0 $8,822.0
2019 $5,428.0 $5,529.0 $5,482.0 $5,680.0 $5,428.0
2018 $5,384.0 $5,780.0 $5,793.0 $5,841.0 $5,384.0
2017 $5,088.0 $4,891.0 $4,859.0 $4,677.0 $5,088.0
2016 $4,758.0 $4,999.0 $5,048.0 $4,753.0 $4,758.0
2015 $4,730.0 $4,574.0 $4,367.0 $4,356.0 $4,730.0
2014 $3,735.0 $3,995.0 $3,811.0 $4,590.0 $3,735.0
2013 $4,803.0 $3,798.0 $3,755.0 $4,299.0 $4,803.0
2012 $4,298.0 $3,097.51 $2,994.01 $3,646.76 $4,298.0
2011 $3,817.0 – – – $3,817.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
© stockrow.com